Question 1

What CDK4/6 inhibitors are FDA-approved and what do they treat?

Accepted Answer

Three CDK4/6 inhibitors are FDA-approved for hormone receptor-positive (HR+), HER2-negative breast cancer: palbociclib (Ibrance, Pfizer) — approved in 2015/2016 for first-line and pre/post-menopausal metastatic disease in combination with letrozole or fulvestrant; ribociclib (Kisqali, Novartis) — approved 2017 for metastatic HR+/HER2- breast cancer in combination with aromatase inhibitor or fulvestrant, including premenopausal women; abemaciclib (Verzenio, Eli Lilly) — approved 2017 for metastatic disease and, critically, in 2021 for the adjuvant setting in high-risk early breast cancer (monarchE trial), the first CDK4/6 inhibitor approval in early-stage disease. All three agents work by inhibiting CDK4 and CDK6 kinases, which drive cell cycle progression from G1 to S phase by phosphorylating the retinoblastoma protein (RB1). In HR+ breast cancer, estrogen signaling drives CDK4/6 activity — combining CDK4/6 inhibition with endocrine therapy produces synergistic cell cycle arrest. The three agents differ in selectivity (palbociclib/ribociclib are more dual CDK4/6-selective; abemaciclib has additional CDK2/9 activity), dosing schedules, and toxicity profiles (all cause neutropenia; abemaciclib causes more diarrhea, less neutropenia).

Question 2

What is the monarchE trial and why does abemaciclib's adjuvant approval matter?

Accepted Answer

The monarchE trial (NCT03155997) was a Phase 3 randomized trial testing abemaciclib plus standard endocrine therapy versus endocrine therapy alone in patients with high-risk, hormone receptor-positive, HER2-negative early breast cancer — specifically patients with ≥4 positive lymph nodes, or 1–3 positive lymph nodes plus either tumor size ≥5cm or grade 3 histology, or Ki-67 ≥20%. The trial demonstrated a statistically significant improvement in invasive disease-free survival (iDFS): at 4-year follow-up, the absolute benefit was approximately 6 percentage points (85.8% vs. 79.4% iDFS). Abemaciclib plus endocrine therapy received FDA approval for this indication in October 2021, and the indication was broadened in 2023 to include patients with ≥4 positive lymph nodes or 1–3 positive lymph nodes plus high Ki-67 (≥20%). This is significant because: (1) it establishes a market in early breast cancer that is far larger than the metastatic setting — approximately 35,000 US patients per year qualify; (2) it creates a template for studying adjuvant CDK4/6 inhibition that Novartis is pursuing for ribociclib (NATALEE trial) and Pfizer has explored for palbociclib (PALLAS trial, which did not meet its primary endpoint — an important competitive differentiation). NATALEE (NCT03701334) showed ribociclib plus endocrine therapy improved iDFS in a somewhat different patient population, and received FDA approval in 2023, creating a three-way competition in the adjuvant setting.

Question 3

What are the mechanisms of resistance to CDK4/6 inhibitors and how are they being addressed in trials?

Accepted Answer

Acquired resistance to CDK4/6 inhibitors is a major clinical challenge. The best-characterized mechanisms include: (1) RB1 loss or mutation — loss of the retinoblastoma protein, the key substrate of CDK4/6, renders CDK4/6 inhibition ineffective; ~15-20% of CDK4/6-resistant tumors; (2) CDK4/6 amplification — increased CDK4 or CDK6 copy number can overwhelm inhibitor binding; (3) PI3K/mTOR pathway activation — through PIK3CA mutation, PTEN loss, or AKT amplification, bypassing the cell cycle checkpoint; drives resistance in approximately 25-30% of cases; (4) CDK2 activation — cyclin E1 amplification or cyclin E1 overexpression allows CDK2 to drive S-phase entry independently of CDK4/6; (5) FGFR1/2 amplification, ESR1 mutations (conferring ligand-independent ER activity). Active trials targeting resistance include: CDK2 inhibitors (INX-315, Incyte; PF-06873600, Pfizer; BLU-222, Blueprint) in cyclin E1-high tumors; PI3K inhibitors (alpelisib/SOLAR-1, inavolisib/INAVO120) + everolimus combinations; PROTAC/degrader approaches that eliminate CDK4/6 rather than inhibit them; and next-generation pan-CDK inhibitors.

Question 4

Is CDK4/6 inhibition being explored in tumor types beyond breast cancer?

Accepted Answer

Yes, CDK4/6 inhibitors are being studied across multiple tumor types beyond HR+ breast cancer, driven by the broad role of the CDK4/6-RB1 pathway in cell cycle regulation. Key expansion areas include: (1) Liposarcoma — CDK4 is amplified in approximately 90% of well-differentiated/dedifferentiated liposarcoma (WD/DDLPS), making it one of the most biologically rational indications outside breast cancer. Palbociclib showed promising Phase 2 activity in CDK4-amplified liposarcoma (PALETTE trial); multiple Phase 2 trials are ongoing; (2) Esophageal/gastric cancer — CDK4/6 inhibitor combinations with checkpoint inhibitors are in Phase 1/2 trials; (3) Non-small cell lung cancer — CDK4/6 inhibitor combinations with EGFR and other targeted therapies; (4) Mantle cell lymphoma — abemaciclib has shown activity; (5) Glioblastoma/glioma — CDK4/6 amplification occurs in subset of GBM; (6) Ovarian cancer — rational combinations with PARP inhibitors; (7) Prostate cancer — CDK4/6 inhibition in CRPC combinations. Most of these indications are in Phase 1/2 with limited data — breast cancer remains the dominant indication accounting for >85% of CDK4/6 trial activity.

Question 5

What are next-generation CDK inhibitors and what do they add over approved agents?

Accepted Answer

Next-generation CDK inhibitors fall into several categories: (1) CDK2 inhibitors — targeting the resistance mechanism driven by cyclin E1 amplification/overexpression. Leading programs: INX-315 (Incyte), PF-06873600 (Pfizer, being studied as monotherapy and in combination with CDK4/6 inhibitors), BLU-222 (Blueprint Medicines). CDK2 inhibitors are in Phase 1/2 and represent a biomarker-driven opportunity in cyclin E1-high tumors. (2) CDK4-selective inhibitors — lerociclib (G1 Therapeutics) and others with modified selectivity profiles; SHR6390 (dalpiciclib, Jiangsu HengRui) is approved in China and in global trials; (3) CDK7 inhibitors — targeting transcriptional regulation as a separate oncogenic dependency; samuraciclib (CT7001), SY-1365, SY-5609 in Phase 1; CDK7 is an upstream activator of CDK1/2/4/6; (4) CDK9 inhibitors — targeting transcriptional elongation; zotiraciclib, alvocidib (flavopiridol) in combination trials; (5) CDK4/6 PROTACs/degraders — molecules that eliminate CDK4/6 protein rather than inhibit kinase activity, potentially effective in contexts where competitive inhibition fails. The most clinically advanced next-gen story is CDK2 inhibitors following CDK4/6 inhibitor failure — this represents a potential second-line opportunity in the large population of patients progressing on approved CDK4/6 agents.

CDK4/6 Inhibitor Clinical Trials — Palbociclib, Ribociclib, Abemaciclib, and the Next-Generation Pipeline 2026

Why CDK4/6 inhibitor trial monitoring matters in 2026

Track CDK inhibitor trial activity daily

The CDK4/6 inhibitor landscape in 2026

Approved agents: differentiating a mature class

CDK2 inhibitors: the post-CDK4/6 resistance opportunity

inavolisib and PI3K pathway combinations

Beyond HR+ breast cancer: CDK4/6 in new tumor types

Who monitors CDK4/6 inhibitor trials

Pharma business development and competitive intelligence teams

Oncology investors and analysts

Breast oncologists and academic investigators

Track CDK inhibitor clinical trial activity

Frequently asked questions

Can I track CDK4/6 inhibitor programs separately from CDK2 inhibitor programs?

Does this cover adjuvant breast cancer trials separately from metastatic?

How do I track new CDK2 inhibitor trial starts before they are widely announced?

Live Trial Data — CDK Inhibitor Trials on ClinicalTrials.gov

Related Pages

Top Sponsors	Trials
Novartis	12
Eli Lilly	11
Roche/Genentech	5
Pfizer	3